Where does Maha Katabi work?

Maha Katabi is General Partner at Sofinnova Ventures.

What does Maha Katabi invest in?

Maha Katabi invests in Biotech, Healthtech, Medical Devices.

What check size does Maha Katabi write?

Maha Katabi typically writes checks of $100K – $5M.

What boards does Maha Katabi sit on?

Maha Katabi holds tracked board seats at Aerovate, Aerovate Therapeutics, Inc., Aiolos, Amplyx, Apellis Pharmaceuticals, Inc., ARTBIO, Coultreon, Effector Therapeutics, Expedition Therapeutics, Gyroscope.

Where did Maha Katabi go to school?

Maha Katabi studied at McGill University (Doctor of Philosophy (PhD), Pharmacology and Therapeutics).

Maha Katabi

Investor

General Partner at Sofinnova Ventures

Montreal

Writes $100K – $5M checks · typically $1.5M

Find your path to Maha

219 people in our graph share verified history with Maha — schools, employers, funds. One of them is your warm intro.

Mattias LjungmanunlockedMaha: together at McGill University (1994–1996)

×7Maha: together at McGill University

×2Maha: together at Rayze Bio

Maha: together at Quanta Therapeutics

About

Maha Katabi is a PhD in Pharmacology and CFA who built crossover public/private biotech investing platforms, focuses on clinical‑stage single‑asset radiopharmaceutical and targeted oncology companies, and chairs Exactis Innovation.

Contact· self-published, not guessed

m•••@sofinnova.comreveal

Invests in

BiotechHealthtechMedical Devices

Experience

Sofinnova InvestmentsGeneral Partnercurrent2020 — present
Sofinnova InvestmentsPartner2019 — 2020
Star TherapeuticsBoard Membercurrent2023 — presentSouth San Francisco, California, United States
Quanta TherapeuticsBoard Membercurrent2021 — presentSan Francisco Bay Area
Marea TherapeuticsBoard Membercurrent2024 — present
ARTBIOBoard Membercurrent2025 — present
Coultreon BiopharmaBoard Membercurrent2026 — present
Vera Therapeutics, Inc.Board Member2020 — 2026Redwood City, California, United States
Exactis InnovationChair of the Board of Directors2019 — 2025
Aiolos BioBoard Member2023 — 2024
RayzeBioBoard Member2022 — 2024San Diego, California, United States
Aerovate Therapeutics, Inc.Board Member2020 — 2024Boston, Massachusetts, United States
GYROSCOPE TxBoard Member2021 — 2022London Area, United Kingdom
NorthSea TherapeuticsBoard Member2019 — 2022Amsterdam, North Holland, Netherlands
Amplyx Pharmaceuticals, IncBoard Member2020 — 2021San Diego, California, United States
Oxalis CapitalManaging Partner2018 — 2019Greater Montreal Metropolitan Area
Sectoral Asset ManagementPartner, Private Equity2008 — 2018
Apellis PharmaceuticalsBoard Member2017Massachusetts, United States
Ventures WestVice-President2004 — 2008
T2C2 CapitalAssociate1999 — 2002

Skills & more

Chartered Financial Analyst (CFA) — CFA Institute
Chartered Financial Analyst Charterholder — CFA Institute

From Maha's professional profile.

Deals · 5

Marea Therapeutics, Inc.Board seat

via Sofinnova Ventures · filed Jun 2024 · $160.4M raise

Gyroscope Therapeutics LtdBoard seat

via Sofinnova Ventures · filed Apr 2021 · $148M raise

Aerovate Therapeutics, Inc.Board seat

via Sofinnova Ventures · filed Aug 2020 · $75.8M raise

Apellis Pharmaceuticals, Inc.Board seat

via Sofinnova Ventures · filed Aug 2017 · $60.1M raise

Effector TherapeuticsBoard seat

via Sofinnova Ventures · filed Feb 2016 · $56M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

AerovateAiolosAmplyxARTBIOCoultreonExpedition TherapeuticsGyroscopeMarea TherapeuticsNorthsea TherapeuticsQuanta Therapeutics Quanta Therapeutics Rayze Bio Rayze BioStar TherapeuticsStar Therapeutics Vera TherapeuticsVera Therapeutics (VERA)

Investor

Apellis Pharmaceuticals (APLS)Ascendis Pharma (ASND)Trius Therapeutics (TSRX-acquired by Cubist)

Sources: the firm's website · SEC Form D filings.

Colleagues at Sofinnova Ventures

Alex Chan

Controller, Private Equity at Sofinnova Ventures

Alex Dulnev

IT Manager at Sofinnova Ventures

Amanda Phillips

Executive Assistant at Sofinnova Ventures

Anastasia Voevodin

Analyst, Public Equity at Sofinnova Ventures

Aneal Tenjarla

Partner, Associate Portfolio Manager, Public Equity at Sofinnova Ventures

Calvin Sternick

Analyst, Public Equity at Sofinnova Ventures

Chris Carpenter

Executive Partner, Private Equity at Sofinnova Ventures

David Kabakoff

Executive Partner, Private Equity at Sofinnova Ventures

Network1

Carl Gordon

Managing Partner at OrbiMed

Investors connected to Maha in public investor directories — a warm-intro map.

Frequently asked questions

Who is Maha Katabi?: Maha Katabi is a PhD in Pharmacology and CFA who built crossover public/private biotech investing platforms, focuses on clinical‑stage single‑asset radiopharmaceutical and targeted oncology companies, and chairs Exactis Innovation.
Where does Maha Katabi work?: Maha Katabi is General Partner at Sofinnova Ventures.
What does Maha Katabi invest in?: Maha Katabi invests in Biotech, Healthtech, Medical Devices.
What check size does Maha Katabi write?: Maha Katabi typically writes checks of $100K – $5M.
What boards does Maha Katabi sit on?: Maha Katabi holds tracked board seats at Aerovate, Aerovate Therapeutics, Inc., Aiolos, Amplyx, Apellis Pharmaceuticals, Inc., ARTBIO, Coultreon, Effector Therapeutics, Expedition Therapeutics, Gyroscope.
What companies has Maha Katabi invested in?: Investments tracked here include Apellis Pharmaceuticals (APLS), Ascendis Pharma (ASND), Trius Therapeutics (TSRX-acquired by Cubist).
Where did Maha Katabi go to school?: Maha Katabi studied at McGill University (Doctor of Philosophy (PhD), Pharmacology and Therapeutics).

Same school

Also attended McGill University652

Harley FinkelsteinInvestor at Felicis Ventures Mattias LjungmanInvestor at Moonfire Ventures Noubar AfeyanInvestor at Flagship Pioneering David NaultGeneral Partner at Luge Capital Laviva MazharPrincipal at Luge Capital Lisa PurcellInvestor at Third Rock Ventures

+ 646 more

Shared employers

Also worked at Sofinnova Investments31

Jonathan BurbaumEntrepreneur-In-Residence at The Innovation Space Jennifer JamesManaging Director, Chief Operating Officer and Head of Investor Relations and Marketing at Thoma Bravo Lars EkmanExecutive Partner, Private Equity at Sofinnova Ventures Perry NisenExecutive Advisor, Private Equity at Sofinnova Ventures Jonathan LeffExecutive Partner, Private Equity at Sofinnova Ventures Chris CarpenterExecutive Partner, Private Equity at Sofinnova Ventures

+ 25 more

Also worked at Coultreon Biopharma8

Pierre RaboissonChief Executive Officer Chief Scientific Officer Co-founder at Coultreon Marie De VulderChief Legal Officer Co-founder at Coultreon Guy PeetersChief Financial Officer Co-founder at Coultreon John-Paul GallivanHead of Development Co-founder at Coultreon Fabrice KolbHead of Immunology Co-founder at Coultreon François GonzalvezCo-founder at Coultreon

+ 2 more

Also worked at Vera Therapeutics, Inc.5

Kurt von EmsterManaging Partner at Abingworth Patrick EnrightManaging Director at Longitude Capital Andrew FraleyCo-founder at Judo Bio Patrick EnrightGeneral Partner at Longitude East Patrick EnrightGeneral Partner at Longitude Prime

Also worked at Amplyx Pharmaceuticals, Inc1

Michael HodgesEntrepreneur in Residence at Claris Ventures